Back to discover
Drug

Volinanserin

In clinical development
ClassSerotonin 2a (5-HT2a) receptor antagonistEmerging researchLate-stage development
RxNorm68760ChEMBLCHEMBL74355UNIIEW71EE171J
1
Research papers
5-hydroxytryptamine receptor 2A
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A non-hallucinogenic LSD analog with therapeutic potential for mood disorders.

Research2023-03-06Cell reports

Efficacy and Safety of 2mg/Day of M100907 on Sleep Maintenance Insomnia With a Sub-study of the Effect of M100907 on Stable Type II Diabetes Mellitus: a One Year, Multi-center, Randomized, Double-blind, Placebo-controlled Study

Clinical trial2009-03-01Terminated · ClinicalTrials.gov

Comparison of the Safety and Efficacy of Volinanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties. A 4 Week,Randomized, Double-blind, Comparative, Parallel-group Study.

Clinical trial2009-01-01Terminated · ClinicalTrials.gov

Efficacy and Safety of 2 mg/Day of M100907 on Sleep Maintenance Insomnia With a Sub-study of the Effect of M100907 on Stable Type II Diabetes Mellitus: a 12-week, Multi-center, Randomized, Double-blind, Placebo-controlled Study

Clinical trial2008-10-01Completed · ClinicalTrials.gov

Efficacy and Safety of 2 mg/Day M100907 on Sleep Maintenance Insomnia: a 6-week, Multicenter, Randomized, Double-blind, Placebo-controlled Polysomnographic Study

Clinical trial2008-01-01Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Volinanserin
RxNorm CUI
68760
ChEMBL ID
CHEMBL74355
UNII
EW71EE171J
Primary mechanism
Serotonin 2a (5-HT2a) receptor antagonist

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

5-hydroxytryptamine receptor 2A
HTR2A · P28223
ANTAGONISTSerotonin 2a (5-HT2a) receptor antagonist

Clinical trials

4 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
4
registered trials across all phases
LATEST COMPLETION 2008
4
Late-stage (III+)
2
Completed
2
Discontinued
PHASE DISTRIBUTIONn = 4
Phase 34

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Efficacy and Safety of 2mg/Day of M100907 on Sleep Maintenance Insomnia With a Sub-study of the Effect of M100907 on Stable Type II Diabetes Mellitus: a One Year, Multi-center, Randomized, Double-blind, Placebo-controlled Study

TerminatedPH IIIKey trialSanofin=1,8472009

Comparison of the Safety and Efficacy of Volinanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties. A 4 Week,Randomized, Double-blind, Comparative, Parallel-group Study.

TerminatedPH IIISanofin=332009

Efficacy and Safety of 2 mg/Day of M100907 on Sleep Maintenance Insomnia With a Sub-study of the Effect of M100907 on Stable Type II Diabetes Mellitus: a 12-week, Multi-center, Randomized, Double-blind, Placebo-controlled Study

CompletedPH IIISanofin=8482008

Efficacy and Safety of 2 mg/Day M100907 on Sleep Maintenance Insomnia: a 6-week, Multicenter, Randomized, Double-blind, Placebo-controlled Polysomnographic Study

CompletedPH IIISanofin=6042008

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes2
Hallucinogens1Lysergic Acid Diethylamide1
Journals, researchers & institutions
Top journals
  • Cell reports1
Leading researchers
  • Abizaid A1
  • Aguilar-Valles A1
  • Arsenault E1
  • Bautista-Carro MA1
  • Bonniwell EM1
  • Calkins MM1
  • Cao AB1
  • El Sayegh F1
Leading institutions
free-text, unnormalised
  • Carleton University1
  • Medical College of Wisconsin1
  • University of California1

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Lysergic Acid Diethylamide

Frequently co-studied with Volinanserin in the research literature.

1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials